Inventor

George A. Martin

Inventor

Berkeley, CA, US

Overview

27→

Patents

1995–2018

Patent span

Chemistry

Primary field (CPC C)

Patents· 27 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides25%

A61KPreparations for medical, dental or toiletry purposes22%

C12NMicroorganisms or enzymes19%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests10%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations9%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms5%

G01NInvestigating or analysing materials by determining their chemical or physical properties5%

B01LChemical or physical laboratory apparatus for general use3%

B60RVehicles, vehicle fittings, or vehicle parts, not otherwise provided for1%

PatentTitleYear

9,952,212In Vitro capture and analysis of circulating tumor cells2018 9,250,242'In vitro capture and analysis of circulating tumor cells'2016 6,204,020'DNA encoding N.gradient.2 CSF-1 (short form) and carboxy truncated fragment thereof'2001 6,156,300'Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof'2000 6,146,851'DNA encoding NV2 (long form) and carboxy truncated fragments thereof'2000 6,117,422'N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof'2000 6,103,224'N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof'2000 6,048,706'Human PAK65'2000 6,022,953'Multifunctional M-CSF proteins and genes encoding therefor'2000 6,013,464'Human PAK65'2000 6,001,605'Gro genes'1999 5,994,060'Gro genes, proteins, and uses thereof'1999 5,977,323'Method of purifying Gro .beta. or Gro .alpha. protein using antibodies'1999 5,874,561'DNA, host cell and vector encoding a protein with cytokine inhibitory activity'1999 5,858,688'Gro genes, proteins, and uses thereof'1999 5,830,684'Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer'1998 5,760,203'Gap gene sequences'1998 5,698,445'Human PAK65'1997 5,698,428'Human PAK65'1997 5,681,719'DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants'1997 5,672,343'N- 3 deletion mutants of the long form of CSF-1'1997 5,643,563'N-.gradient.3 deletion mutants of the short form of CSF-1'1997 5,605,825'Human PAK65'1997 5,573,930'DNA encoding various forms of colony stimulating factor-1'1996 5,567,611'Multifunctional M-CSF proteins and genes encoding therefor'1996 5,518,911'Human PAK65'1996 5,455,330'Interleukin-1 antagonist and uses thereof'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–1996Patents assigned to CETUS ONCOLOGY CORP (2)· patent assignee history

1995–2018Based in Berkeley, CA, US· patent location history

1996–2000Patents assigned to ONYX PHARMA INC (6)· patent assignee history

1997–2001Patents assigned to CHIRON CORP (16)· patent assignee history

1999–2016Patents assigned to UNIV NORTH CAROLINA (4)· patent assignee history

2016–2018Patents assigned to ROCHE MOLECULAR SYSTEMS INC (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
CHIRON CORP	16	1997–2001
ONYX PHARMA INC	6	1996–2000
UNIV NORTH CAROLINA	4	1999–2016
CETUS ONCOLOGY CORP	2	1995–1996
ROCHE MOLECULAR SYSTEMS INC	2	2016–2018

Locations

Location	Patents	Span
Berkeley, California, US	27	1995–2018